GlaxoSmithKline is trading 4.89% down now at $48.45 after its October 28, 2026, third-quarter report disappointed investors on vaccine sales, which fell 2%.
- The report beat headline earnings and revenue estimates, but Shingrix and Arexvy sales were weaker.
- A £328 million restructuring charge weighed on reported profitability; investors were also unconvinced by pipeline-building plans and the cost-savings drive.
- The broader UK pharmaceutical and biotechnology sector was down 1.7%.